Breast Cancer Brain Metastasis — When Breast Cancer Spreads to the Brain

Many symptoms are driven by the swelling (oedema) around a lesion rather than the lesion itself. Corticosteroids reduce this swelling and can ease headache, weakness and confusion within days — often before any radiation or surgery. If you have had a seizure, anti-seizure medication is started and managed by the team. These supportive steps are usually the first thing we put in place, because feeling better quickly matters, and because a calmer, clearer patient can take part in the bigger treatment decisions that follow.

Stereotactic radiosurgery delivers a high, focused dose of radiation to each metastasis from many angles at once, without any incision — despite the word "surgery", no cutting is involved. It is delivered as part of coordinated specialist radiation care and is often preferred over whole-brain radiation when the number of lesions is limited, because it spares much of the healthy brain and better preserves memory and thinking. Treatment is usually completed in 1 to 5 outpatient sessions. Modern guidelines support treating several metastases this way rather than defaulting to whole-brain radiation.

For HER2-positive breast cancer, this is often the most important advance. Several modern HER2-directed therapies — described here by drug class rather than brand — can cross into the brain and shrink metastases, in addition to focused radiation. This is why a HER2 brain metastasis is frequently very treatable, and why the plan usually combines brain-directed radiation with HER2-targeted systemic therapy chosen by the medical oncologist. Confirming HER2 status is essential before this pathway is used, and it is one of the strongest reasons to seek a second opinion before treatment begins.

Because brain metastases carry the same receptors as the breast cancer, systemic (whole-body) therapy is chosen to match your subtype. For hormone-receptor-positive disease this may be endocrine (hormone) therapy; for triple-negative disease, chemotherapy or, depending on molecular features, immunotherapy (all described by class, not brand). Some of these treatments help the brain lesions as well as the rest of the body. CION's medical oncology team delivers systemic therapy directly and coordinates it with your radiation plan through the tumour board.

Whole-brain radiation treats the entire brain and is used in selected situations — for example when there are many lesions, or when tiny deposits are likely beyond what a scan shows. It can be very effective at controlling disease, but because it treats healthy brain too, it can affect memory and thinking, so it is weighed carefully against focused radiosurgery. If whole-brain radiation has been recommended to you, it is reasonable to ask whether radiosurgery is an option first — a common reason patients seek a second opinion. Techniques that protect the memory centres (hippocampal-sparing) may also be discussed.

Surgery is considered mainly for a large single metastasis causing significant pressure, or when tissue is needed to confirm the diagnosis. Removing such a lesion can relieve symptoms quickly and is often followed by focused radiation to the surgical bed. CION does not perform neurosurgery in-house; all neurosurgical steps — resection, stereotactic biopsy, neuronavigation — are coordinated with accredited neurosurgical partners, while CION delivers the imaging, radiation planning, systemic therapy and supportive care directly. The tumour board decides together whether surgery, radiosurgery or systemic therapy leads for your situation.

Alongside cancer-directed treatment, supportive care protects how you feel and function day to day. This can include physiotherapy for weakness, speech therapy, help with memory and fatigue, pain and nausea control, and emotional and family support. Because a brain-metastasis diagnosis affects the whole family, we make time to explain what is happening and what to expect. Our approach is to make decisions for healing, not billing — with transparent costs discussed up front, so you can focus on getting the care you need.

Breast cancer brain metastasis means breast-cancer cells have spread to the brain and formed one or more secondary tumours there. It is also called secondary brain cancer or "brain mets". Importantly, these are not a new primary brain tumour — under the microscope the cells are still breast-cancer cells, which is why treatment is matched to the breast cancer as well as the brain lesions. Brain metastases are the most common brain tumour in adults. To understand the wider picture, see our guide on which cancers spread to the brain and the breast cancer hub.

The risk of brain spread depends heavily on the subtype of breast cancer. HER2-positive and triple-negative breast cancers spread to the brain more often than hormone-receptor-positive disease. This is why your breast cancer's receptor status (ER, PR, HER2) is central to planning care. Knowing the subtype also decides which modern targeted or immune therapies — described here by class, not brand — may reach the brain and help. If you are unsure of your subtype, our team can review your reports during a free 45-minute consultation.

Symptoms depend on where the lesions sit and the swelling around them. Watch for signs that are new, persistent and progressive: a new headache pattern (often worse in the morning or with coughing), a first-ever seizure, one-sided weakness or numbness, trouble with speech or vision, unsteady balance, and changes in memory or personality that family notice first. Many people have more than one. If you are living with breast cancer and develop any new neurological symptom, ask your oncologist about a brain MRI. For more detail, see brain metastases symptoms.

HER2-positive breast cancer has a higher tendency to spread to the brain, but it is also one of the situations where treatment has advanced most. Several modern HER2-directed therapies (a drug class, not a single brand) can cross into the brain and shrink lesions, in addition to focused radiation. This means a HER2 brain metastasis is often very treatable, and the plan usually combines brain-directed radiation with HER2-targeted systemic therapy chosen by the medical oncologist. Molecular and receptor testing on your cancer decides which options apply — a key reason a second opinion is worthwhile before treatment begins.

The key test is a contrast-enhanced MRI of the brain — the most sensitive way to find and map lesions, showing their number, size and location and the swelling around them. A CT scan is used first in emergencies to rule out bleeding. Because the primary cancer (breast) is usually already known, a brain biopsy is rarely needed. Any neurosurgical step, if required, is coordinated with accredited neurosurgical partners; CION delivers the imaging, molecular and receptor testing, radiation planning and systemic therapy directly, and reviews every case at a tumour board following NCCN and EANO guidance.

Treatment has two aims — relieve symptoms and control the lesions. Steroids reduce swelling and can ease headache and weakness within days, and anti-seizure medicine controls seizures. Stereotactic radiosurgery delivers precise, high-dose radiation to each lesion (as part of coordinated specialist radiation care) and is often preferred when lesions are limited, because it spares more healthy brain than whole-brain radiation. Systemic therapy — HER2-directed therapy, endocrine therapy, immunotherapy or chemotherapy chosen for the breast cancer subtype — can shrink brain lesions too. Surgery, coordinated with neurosurgical partners, is used for large single lesions.

There is no single survival number — the outlook varies widely and depends mainly on the breast cancer subtype (HER2-positive, triple-negative or hormone-receptor-positive), the number of lesions, your general fitness, and how well the cancer responds to treatment. Modern HER2-directed and other systemic therapies have genuinely improved outcomes, and focused radiosurgery controls many lesions well. Both NCCN and EANO stress an individualised plan rather than a fixed prognosis. Your team will explain what the evidence means for your situation, sensitively and honestly — never as a guarantee. To start, book a free 45-minute consultation.